April 22, 2015
Nutra Pharma Has Announced That They Have Engaged the Vancouver Commodities Group to Begin the Process of Distributing Nyloxin(R) in the People's Republic of China
CORAL SPRINGS, FL--(Marketwired - Apr 22, 2015) - Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin®.
"We recently announced that the first test orders of Nyloxin have gone out to our distributors in India," stated Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "This news of international expansion has brought several exciting opportunities to Nutra Pharma, including the introduction of consultants that have the ability to identify foreign markets as well as aid in drug registration, approval and distribution," he continued. "Our consultants at VCG have already introduced Nyloxin to potential distributors in China and they believe that we can move the approval process forward expeditiously," he concluded.
China is currently the world's most populous country with almost 1.4B people. According to Research & Markets, the analgesics drug category in China was worth $1.2 billion in 2014 and was dominated by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and topical ointments.
"We are extremely pleased to be working with Nutra Pharma Corp.," commented Robert Cymbala, Managing Director of Vancouver Commodities Group. "We have already received favorable reactions both from Government agencies within the Peoples Republic of China and from private Pharma companies in the region with strong distribution capabilities," he continued. "We view this as a first step in broadening distribution into Asia. We also believe that it is possible that other areas in the region such as Hong Kong and Singapore will be very receptive to Nutra Pharma's Products," he concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away.
For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The engagement of VCG should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.